# A Study to Assess the Pharmacokinetics of Sorafenib in Mesoporous Magnesium Carbonate (DPH001) Compared to Nexavar® (sorafenib) in Healthy Volunteers

> **NCT06797427** · EARLY_PHASE1 · COMPLETED · sponsor: **Disruptive Pharma** · enrollment: 12 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** DPH001
- **DRUG:** Nexavar (Sorafenib)

## Key facts

- **NCT ID:** NCT06797427
- **Lead sponsor:** Disruptive Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-02-10
- **Primary completion:** 2025-03-10
- **Final completion:** 2025-03-10
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-03-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06797427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06797427, "A Study to Assess the Pharmacokinetics of Sorafenib in Mesoporous Magnesium Carbonate (DPH001) Compared to Nexavar® (sorafenib) in Healthy Volunteers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06797427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*